MedPath

PreAsthmaControl (PAC)

Phase 4
Completed
Conditions
Asthma
Registration Number
NCT00234390
Lead Sponsor
AstraZeneca
Brief Summary

The purpose of this study is to investigate the ability of budesonide, given during episodes of troublesome lung symptoms to reduce further symptoms in infants and young children at risk of developing asthma

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
400
Inclusion Criteria
  • Children of asthmatic mothers form the COPSAC birth cohort study
Exclusion Criteria
  • Children born more than 4 weeks preterm
  • children with other systemic illness that atopy/allergy
  • Children requiring mechanical ventilation at any time since birth.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
days with no use of bronchodilator and no symptoms
number of treated episodes
number of treatment with add-on medication
days with no use of bronchodilator
symptom free days
Secondary Outcome Measures
NameTimeMethod
asthma status
number of patients who needed add-on medication
BMD
height
the total steroid dose
First treatment episode:
number of symptom days
number of days with use of bronchodilator
time to start of algorithm treatment
serious adverse events

Trial Locations

Locations (1)

Research Site

🇩🇰

Copenhagen, Denmark

© Copyright 2025. All Rights Reserved by MedPath